PRF1 and acute myeloid leukemia: (4) Finally, AML patients with higher pre-treatment levels of perforin in T cells, higher in vitro IFN-γ response by CD8+ T cells, and lower plasma levels of IFN-γ went on to exhibit venetoclax resistance.